Do patients with acute myocardial infarction benefit from treatment with clopidogrel?

Abstract

Clopidogrel (Plavix), a platelet aggregation inhibitor, has been shown to be effective in certain patients undergoing percutaneous coronary interventions, but its use in patients with acute myocardial infarction who receive a fibrinolytic strategy instead has been controversial. The aim of the Evidence-Based Medicine (EBM) Section is to bring the readership clinically relevant and practical evidence-based medicine principles and topic reviews. This EBM - Therapy review focuses on a relatively new therapy option for Emergency Department patients with acute myocardial infarction.

• Authors: Andrew Worster, Samuel M Keim, Rajiv Vadera, Peter Rosen
• Journal: The Journal of emergency medicine (J Emerg Med) Vol. 34 Issue 4 Pg. 479-83; discussion 483 (May 2008) ISSN: 0736-4679 [Print] United States
• PMID: 18226876 (Publication Type: Journal Article, Review)

Chemical References

• Platelet Aggregation Inhibitors
• Clopidogrel
• Ticlopidine

Topics

• Adult
• Clopidogrel
• Emergency Medical Services
• Evidence-Based Medicine
• Humans
• Male
• Myocardial Infarction (drug therapy)
• Platelet Aggregation Inhibitors (therapeutic use)
• Randomized Controlled Trials as Topic
• Ticlopidine (analogs & derivatives, therapeutic use)